478 completed, 169 unknown, 161 recruiting, 160 terminated. 696 Phase 2, 285 Phase 1, 270 Phase 3, 52 Not applicable, 27 Phase 4.
Follow Pemetrexed: new trials by email Literature Review of Pemetrexed trials Research Report on Pemetrexed
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer Biospecimen Collection, Carboplatin, Computed Tomography - Lung Non-Squamous Non-Small Cell Carcinoma | Phase 2 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 16 | 2027-06-01 | 2026-02-05 |
| Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung Cancer LND101, Carboplatin (AUC 5 or 6), pemetrexed - Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Canadian Cancer Trials Group | 160 | 2026-12-31 | 2026-10-22 |
| PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50% Pembrolizumab, Carboplatin (AUC 5), Cisplatin (75 mg/m²) - Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | German Cancer Research Center | 406 | 2026-11-30 | 2026-10-16 |
| A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220) Pumitamig, Carboplatin, Cisplatin - Early-Stage Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Bristol-Myers Squibb | 80 | 2026-11-30 | 2026-10-13 |
| A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Investigational drug: HLX37 dose1, IV, Q3W, PEMBROLIZUMAB (alone or when added to a regimen above), Carboplatin (Investigator discretion) - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Henlius Biotech | 1438 | 2026-11-30 | 2026-10-08 |
| Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer Cemiplimab, Carboplatin + Pemetrexed/Paclitaxel, Cisplatin - Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Medical University of South Carolina | 38 | 2026-11-01 | 2026-07-22 |
| MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLC Aumolertinib, Pemetrexed, Carboplatin - Non-Small Cell Lung Cancer | Not applicable | Not yet recruiting | Peking University People's Hospital | 50 | 2026-11-01 | 2026-10-14 |
| This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation. GFH276, with or without Tislelizumab, Pemetrexed - RAS Mutation, Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | 84 | 2026-11-01 | 2026-09-29 |
| Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets Ivonescimab, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 158 | 2026-11-01 | 2026-06-04 |
| MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC PD-1 inhibitor, Carboplatin, Nab-paclitaxel - Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Peking University People's Hospital | 100 | 2026-11-01 | 2026-10-21 |
| Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer Tocilizumab, Pembrolizumab, Platinum-Doublet Chemotherapy - Metastatic Non-Small Cell Lung Cancer, Cancer-Associated Weight Loss | Phase 1 / Phase 2 | Not yet recruiting | VA Office of Research and Development | 43 | 2026-11-01 | 2026-10-22 |
| A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer HS-10370, Adebrelimab, Cisplatin - Carcinoma, Non-Small-Cell Lung | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 448 | 2026-10-31 | 2026-09-16 |
| A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) MK-2010, Pembrolizumab, 5-Fluorouracil - Malignant Neoplam, Advanced Solid Tumors | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 480 | 2026-10-27 | 2026-10-08 |
| Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 60 | 2026-10-27 | 2026-10-22 |
| Quad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer Quad Shot Radiotherapy, Tislelizumab, Carboplatin or cisplatin - Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 12 | 2026-10-10 | 2026-09-29 |
| A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation Sosimerasib in combination with IN10018, Tislelizumab + Carboplatin + Pemetrexed - NSCLC | Phase 3 | Not yet recruiting | Shanghai Jeyou Pharmaceutical Co., Ltd. | 416 | 2026-10-01 | 2026-09-24 |
| A Study of DS-3939a in Participants With Solid Tumors DS-3939a, Pembrolizumab, Carboplatin - Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | Daiichi Sankyo | 400 | 2026-10-01 | 2026-07-31 |
| Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas Golcadomide, Pemetrexed, Rituximab - Large B-cell Lymphoma, Central Nervous System Lymphoma | Phase 1 | Not yet recruiting | Allison Winter | 18 | 2026-10-01 | 2026-08-21 |
| Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations RC148 Injection plus Pemetrexed Disodium for Injection and Carboplatin Injection, Tislelizumab Injection plus Pemetrexed Disodium for Injection and Carboplatin Injection - Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations | Phase 3 | Not yet recruiting | RemeGen Co., Ltd. | 540 | 2026-09-30 | 2026-09-22 |
| Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC HS-10504, platinum-based doublet chemotherapy (Pemetrexed and Cisplatin/Carboplatin) - Advanced or Metastatic NSCLC | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 206 | 2026-09-17 | 2026-08-10 |
Showing 20 of 1201. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (632) · Lung Neoplasms (193) · Neoplasms (69) · Neoplasm Metastasis (50) · Mesothelioma, Malignant (46) · Adenocarcinoma of Lung (42) · Mesothelioma (40) · Colorectal Neoplasms (31) · Carcinoma (24) · Breast Neoplasms (23) · Meningeal Carcinomatosis (20) · Parkinson Disease 4, Autosomal Dominant Lewy Body (20) · Head and Neck Neoplasms (19) · Brain Neoplasms (18) · Ovarian Neoplasms (17)
Eli Lilly and Company (122) · Merck Sharp & Dohme LLC (39) · AstraZeneca (32) · Bristol-Myers Squibb (27) · Hoffmann-La Roche (24) · National Cancer Institute (NCI) (22) · M.D. Anderson Cancer Center (16) · Alliance for Clinical Trials in Oncology (14) · Memorial Sloan Kettering Cancer Center (14) · Sun Yat-sen University (13) · Pfizer (12) · Boehringer Ingelheim (10) · Fudan University (10) · Hunan Province Tumor Hospital (10) · Tianjin Medical University Cancer Institute and Hospital (10)
United States (556) · China (370) · Spain (216) · France (185) · Italy (179) · South Korea (179) · Germany (169) · Taiwan (135) · Canada (131) · Japan (129) · Australia (128) · United Kingdom (123) · Poland (118) · Belgium (113) · Brazil (98)
David S. Miller, MD (5) · Yongchang Zhang, MD (5)
PMID 33358660, PMID 29658856, PMID 37465924, PMID 15117425, PMID 16391300, PMID 22266043, PMID 23726971, PMID 23835707, PMID 25371077, PMID 27130468, PMID 27243238, PMID 27718847, PMID 27745820, PMID 30955977, PMID 32781263, PMID 32997907, PMID 33231285, PMID 33661301, PMID 35048355, PMID 35073727, PMID 35511917, PMID 36053283, PMID 36795388, PMID 37419867, PMID 38383458, PMID 38642841, PMID 39369790, PMID 40311309, PMID 41747891, PMID 42579028, PMID 9533527, PMID 10501910, PMID 11001674, PMID 11531245, PMID 11602624, PMID 11698646, PMID 11844814, PMID 14059058, PMID 1447744, PMID 14691125, PMID 14985505, PMID 15030777, PMID 15240681, PMID 15261145, PMID 15358536, PMID 15771580, PMID 15800326, PMID 16012180, PMID 16135464, PMID 16227604
2023 (46), 2018 (20), 2016 (13), 2017 (13), 2015 (11), 2019 (10), 2025 (10), 2014 (8), 2009 (7), U10CA180888 (7), U10CA180821 (6), 2008 (5), P30CA022453 (5), U10CA180820 (5), U10CA180868 (5)